Mark A Atkinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1671898/publications.pdf

Version: 2024-02-01

277 papers

25,004 citations

74 h-index 9346 148 g-index

329 all docs

329 docs citations

times ranked

329

22120 citing authors

#	Article	IF	Citations
1	Improving the Prediction of Type 1 Diabetes Across Ancestries. Diabetes Care, 2022, 45, e48-e50.	4.3	7
2	The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still. Lancet Diabetes and Endocrinology,the, 2022, 10, 90-92.	5.5	8
3	Exploration of autoantibody responses in canine diabetes using protein arrays. Scientific Reports, 2022, 12, 2490.	1.6	3
4	Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Reports, 2022, 38, 110508.	2.9	36
5	Response to Comment on Dunne et al. The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes Care 2021;44:1734–1743. Diabetes Care, 2022, 45, e99-e99.	4.3	O
6	Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas. American Journal of Pathology, 2021, 191, 454-462.	1.9	19
7	Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes. Diabetes, 2021, 70, 313-322.	0.3	9
8	Index60 as an additional diagnostic criterion for type 1 diabetes. Diabetologia, 2021, 64, 836-844.	2.9	13
9	Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis. Diabetes, 2021, 70, 932-943.	0.3	8
10	Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size. Diabetes, 2021, 70, 944-954.	0.3	20
11	Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. Genome Biology, 2021, 22, 39.	3.8	22
12	Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes, 2021, 70, 1123-1129.	0.3	11
13	TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes. Cell, 2021, 184, 827-839.e14.	13.5	16
14	Proinsulin-Reactive CD4 T Cells in the Islets of Type 1 Diabetes Organ Donors. Frontiers in Endocrinology, 2021, 12, 622647.	1.5	20
15	Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes. Scientific Reports, 2021, 11 , 6562.	1.6	18
16	Insulin Receptor–Expressing T Cells Appear in Individuals at Risk for Type 1 Diabetes and Can Move into the Pancreas in C57BL/6 Transgenic Mice. Journal of Immunology, 2021, 206, 1443-1453.	0.4	2
17	Observing Islet Function and Islet-Immune Cell Interactions in Live Pancreatic Tissue Slices. Journal of Visualized Experiments, 2021, , .	0.2	7
18	Altered Î ² -Cell Prohormone Processing and Secretion in Type 1 Diabetes. Diabetes, 2021, 70, 1038-1050.	0.3	28

#	Article	IF	Citations
19	Monogenic Diabetes and Integrated Stress Response Genes Display Altered Gene Expression in Type 1 Diabetes. Diabetes, 2021, 70, 1885-1897.	0.3	7
20	Peripheral immune circadian variation, synchronisation and possible dysrhythmia in established type 1 diabetes. Diabetologia, 2021, 64, 1822-1833.	2.9	6
21	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nature Genetics, 2021, 53, 962-971.	9.4	133
22	The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes Care, 2021, 44, 1734-1743.	4.3	15
23	The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes, 2021, 70, 1623-1633.	0.3	10
24	Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes?. Lancet Diabetes and Endocrinology,the, 2021, 9, 328-329.	5 . 5	23
25	The influence of selection bias on identifying an association between allergy medication use and SARS-CoV-2 infection. EClinicalMedicine, 2021, 37, 100936.	3.2	6
26	Delayed diagnosis of diabetic ketoacidosis and associated mortality during the COVID \hat{a} pandemic. Journal of Diabetes, 2021, 13, 837-839.	0.8	0
27	Overexpression of the <i>PTPN22</i> Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation. Journal of Immunology, 2021, 207, 849-859.	0.4	7
28	Altered cellular localisation and expression, together with unconventional protein trafficking, of prion protein, PrPC, in type 1 diabetes. Diabetologia, 2021, 64, 2279-2291.	2.9	7
29	Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. Diabetes Care, 2021, 44, 2329-2336.	4.3	5
30	ACE2 chromogenic immunostaining protocol optimized for formalin-fixed paraffin-embedded human tissue sections. STAR Protocols, 2021, 2, 100696.	0.5	1
31	Defining a cure for type 1 diabetes: a call to action. Lancet Diabetes and Endocrinology,the, 2021, 9, 553-555.	5. 5	12
32	Human islet T cells are highly reactive to preproinsulin in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	3.3	42
33	Single-cell analysis of the human pancreas in type 2 diabetes using multi-spectral imaging mass cytometry. Cell Reports, 2021, 37, 109919.	2.9	33
34	Substance Use Affects Type 1 Diabetes Pancreas Pathology: Implications for Future Studies. Frontiers in Endocrinology, 2021, 12, 778912.	1.5	0
35	Targeted metabolomic analysis identifies increased serum levels of GABA and branched chain amino acids in canine diabetes. Metabolomics, 2021, 17, 100.	1.4	4
36	geneBasis: an iterative approach for unsupervised selection of targeted gene panels from scRNA-seq. Genome Biology, 2021, 22, 333.	3.8	15

#	Article	IF	CITATIONS
37	Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers Through Undergraduate Research Curriculum. Medical Science Educator, 2020, 30, 69-73.	0.7	1
38	Temporal Analysis of Amylase Expression in Control, Autoantibody-Positive, and Type 1 Diabetes Pancreatic Tissues. Diabetes, 2020, 69, 60-66.	0.3	18
39	Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes, 2020, 69, 413-423.	0.3	29
40	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia, 2020, 63, 588-596.	2.9	58
41	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	4.3	220
42	Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1629-1640.	1.8	15
43	CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation. Frontiers in Immunology, 2020, 11, 2180.	2.2	21
44	Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metabolism, 2020, 32, 1041-1051.e6.	7.2	135
45	Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses. Frontiers in Immunology, 2020, $11,574447.$	2.2	18
46	Removing Formaldehydeâ€Induced Peptidyl Crosslinks Enables Mass Spectrometry Imaging of Peptide Hormone Distributions from Formalinâ€Fixed Paraffinâ€Embedded Tissues. Angewandte Chemie - International Edition, 2020, 59, 22584-22590.	7.2	8
47	Diabetes Leads to Alterations in Normal Metabolic Transitions of Pregnancy as Revealed by Time-Course Metabolomics. Metabolites, 2020, 10, 350.	1.3	19
48	Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 948-953.	2.4	41
49	Removing Formaldehydeâ€Induced Peptidyl Crosslinks Enables Mass Spectrometry Imaging of Peptide Hormone Distributions from Formalinâ€Fixed Paraffinâ€Embedded Tissues. Angewandte Chemie, 2020, 132, 22773-22779.	1.6	0
50	Organisation of the human pancreas in health and in diabetes. Diabetologia, 2020, 63, 1966-1973.	2.9	62
51	Evaluation for type 1 diabetes associated autoantibodies in diabetic and non-diabetic Australian terriers and Samoyeds. Canine Medicine and Genetics, 2020, 7, 10.	1.4	4
52	Pancreatlas: Applying an Adaptable Framework to Map the Human Pancreas in Health and Disease. Patterns, 2020, 1, 100120.	3.1	8
53	Large-scale electron microscopy database for human type 1 diabetes. Nature Communications, 2020, 11 , 2475 .	5.8	51
54	Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. Frontiers in Immunology, 2020, 11, 1103.	2.2	19

#	Article	IF	Citations
55	Obesity Treatment Among Adolescents. JAMA Pediatrics, 2020, 174, 609.	3.3	112
56	Long-term culture of human pancreatic slices as a model to study real-time islet regeneration. Nature Communications, 2020, 11, 3265.	5.8	34
57	Commercially Available Insulin Products Demonstrate Stability Throughout the Cold Supply Chain Across the U.S Diabetes Care, 2020, 43, 1360-1362.	4.3	4
58	An Intolerable Burden: Suicide, Intended Self-Injury and Diabetes. Canadian Journal of Diabetes, 2020, 44, 541-544.	0.4	6
59	Early and late Câ€peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibodyâ€positive individuals. Diabetes, Obesity and Metabolism, 2020, 22, 997-1000.	2.2	5
60	Synchronization of the Normal Human Peripheral Immune System: A Comprehensive Circadian Systems Immunology Analysis. Scientific Reports, 2020, 10, 672.	1.6	19
61	Innate inflammation drives NK cell activation to impair Treg activity. Journal of Autoimmunity, 2020, 108, 102417.	3.0	36
62	Pancreas tissue slices from organ donors enable in situ analysis of type 1 diabetes pathogenesis. JCI Insight, 2020, 5 , .	2.3	53
63	Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic $\rm l^2$ cells. JCI Insight, 2020, 5, .	2.3	34
64	Exocrine Pancreas Dysfunction in Type 1 Diabetes. Endocrine Practice, 2020, 26, 1505-1513.	1.1	18
65	Islet Microvasculature Alterations With Loss of Beta-cells in Patients With Type 1 Diabetes. Journal of Histochemistry and Cytochemistry, 2019, 67, 41-52.	1.3	31
66	Genetic risk for autoimmunity is associated with distinct changes in the human gut microbiome. Nature Communications, 2019 , 10 , 3621 .	5.8	132
67	Clinical features, biochemistry and HLA-DRB1 status in children and adolescents with diabetes in Dhaka, Bangladesh. Diabetes Research and Clinical Practice, 2019, 158, 107894.	1.1	14
68	Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes. Journal of Clinical Medicine, 2019, 8, 1321.	1.0	11
69	Characterization of Non-hormone Expressing Endocrine Cells in Fetal and Infant Human Pancreas. Frontiers in Endocrinology, 2019, 9, 791.	1.5	2
70	A Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry. Cell Metabolism, 2019, 29, 755-768.e5.	7.2	217
71	Multiplexed In Situ Imaging Mass Cytometry Analysis of the Human Endocrine Pancreas and Immune System in Type 1 Diabetes. Cell Metabolism, 2019, 29, 769-783.e4.	7.2	151
72	Type 1 Diabetes Risk in African-Ancestry Participants and Utility of an Ancestry-Specific Genetic Risk Score. Diabetes Care, 2019, 42, 406-415.	4.3	62

#	Article	IF	CITATIONS
73	NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). Diabetes, 2019, 68, 1394-1402.	0.3	69
74	Islet amyloidosis in a child with type 1 diabetes. Islets, 2019, 11, 44-49.	0.9	17
75	The Influence of Type 2 Diabetes–Associated Factors on Type 1 Diabetes. Diabetes Care, 2019, 42, 1357-1364.	4.3	30
76	Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. Diabetologia, 2019, 62, 1100-1103.	2.9	4
77	Boosting to Amplify Signal with Isobaric Labeling (BASIL) Strategy for Comprehensive Quantitative Phosphoproteomic Characterization of Small Populations of Cells. Analytical Chemistry, 2019, 91, 5794-5801.	3.2	86
78	Clinical features, biochemistry and HLA-DRB1 status in youth-onset type 1 diabetes in Pakistan. Diabetes Research and Clinical Practice, 2019, 149, 9-17.	1.1	12
79	Increased risk for T cell autoreactivity to ß-cell antigens in the mice expressing the Avy obesity-associated gene. Scientific Reports, 2019, 9, 4269.	1.6	1
80	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.3	80
81	Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model. ACS Biomaterials Science and Engineering, 2019, 5, 2631-2646.	2.6	58
82	Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia, 2019, 62, 744-753.	2.9	65
83	Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. Cell Metabolism, 2019, 29, 1045-1060.e10.	7.2	232
84	Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care, 2019, 42, 2228-2236.	4.3	18
85	Interleukin-27 Is Essential for Type 1 Diabetes Development and Sjögren Syndrome-like Inflammation. Cell Reports, 2019, 29, 3073-3086.e5.	2.9	32
86	Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 188-194.	1.2	7
87	Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 281-287.	4.3	80
88	The challenge of modulating \hat{l}^2 -cell autoimmunity in type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2019, 7, 52-64.	5.5	124
89	α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes. Cell Reports, 2018, 22, 2667-2676.	2.9	152
90	Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles. Diabetes, 2018, 67, 697-703.	0.3	24

#	Article	IF	Citations
91	Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in KCNJ11, HNF1A, GATA6, and LMNA. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 35-45.	1.8	17
92	Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. Scientific Reports, 2018, 8, 4529.	1.6	59
93	Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. Diabetes Care, 2018, 41, 653-661.	4.3	55
94	Hospital time prior to death and pancreas histopathology: implications for future studies. Diabetologia, 2018, 61, 954-958.	2.9	5
95	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetesâ€"The TrialNet Experience. Diabetes, 2018, 67, 1216-1225.	0.3	29
96	Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes. Diabetes, 2018, 67, 2038-2053.	0.3	17
97	Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus. Frontiers in Immunology, 2018, 9, 1053.	2.2	4
98	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves \hat{l}^2 -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	4.3	114
99	Nanowell-mediated two-dimensional liquid chromatography enables deep proteome profiling of <1000 mammalian cells. Chemical Science, 2018, 9, 6944-6951.	3.7	33
100	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care, 2018, 41, 1887-1894.	4.3	104
101	Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. Journal of Clinical Investigation, 2018, 128, 1888-1902.	3.9	43
102	Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy - Methods and Clinical Development, 2017, 4, 178-191.	1.8	62
103	Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?. Diabetologia, 2017, 60, 753-755.	2.9	7
104	Serum Trypsinogen Levels in Type 1 Diabetes. Diabetes Care, 2017, 40, 577-582.	4.3	40
105	Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice. Scientific Reports, 2017, 7, 42372.	1.6	20
106	Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes. Journal of Immunology, 2017, 198, 4255-4267.	0.4	25
107	Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?. Diabetes, 2017, 66, 1443-1452.	0.3	41
108	Mary Tyler Moore (1936–2017): Diabetes Educator and Advocate. Diabetes Care, 2017, 40, 732-735.	4.3	1

#	Article	IF	CITATIONS
109	Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes, 2017, 66, 722-734.	0.3	154
110	Association Between Early-Life Antibiotic Use and the Risk of Islet or Celiac Disease Autoimmunity. JAMA Pediatrics, 2017, 171, 1217.	3.3	79
111	Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. Journal of Immunology, 2017, 199, 3757-3770.	0.4	26
112	Type 1 Interferons Potentiate Human CD8+ T-Cell Cytotoxicity Through a STAT4- and Granzyme B–Dependent Pathway. Diabetes, 2017, 66, 3061-3071.	0.3	56
113	T cells display mitochondria hyperpolarization in human type 1 diabetes. Scientific Reports, 2017, 7, 10835.	1.6	34
114	Response to Comment on Rodriguez-Calvo et al. Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset. Diabetes 2017;66:1334–1345. Diabetes, 2017, 66, e10-e11.	0.3	2
115	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care, 2017, 40, 1494-1499.	4.3	28
116	Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata. Cell Metabolism, 2017, 26, 568-575.e3.	7.2	77
117	Proteoliposome-based full-length ZnT8 self-antigen for type 1 diabetes diagnosis on a plasmonic platform. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10196-10201.	3.3	31
118	Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. Scientific Reports, 2017, 7, 9467.	1.6	36
119	High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes Care, 2017, 40, e122-e123.	4.3	6
120	\hat{l}^2 -Cell mass versus function in type 1 diabetes mellitus: truth or dare?. Nature Reviews Endocrinology, 2017, 13, 1-1.	4.3	3
121	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia, 2017, 60, 35-38.	2.9	28
122	Tracking the Antibody Immunome in Type 1 Diabetes Using Protein Arrays. Journal of Proteome Research, 2017, 16, 195-203.	1.8	38
123	Impact of blood collection and processing on peripheral blood gene expression profiling in type 1 diabetes. BMC Genomics, 2017, 18, 636.	1.2	9
124	Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Frontiers in Immunology, 2017, 8, 655.	2.2	73
125	Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays. Diabetes, 2016, 65, 285-296.	0.3	59
126	Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface. Journal of Diabetes Research, 2016, 2016, 1-4.	1.0	8

#	Article	IF	Citations
127	Type 1 Diabetes Mellitus. , 2016, , 1451-1483.		5
128	Pancreatic duct hyperplasia/dysplasia in type 1 diabetes and pancreatic weight in individuals with and without diabetes. Reply to Kobayashi T, Aida K, Fukui T et al [letter] and Saisho Y [letter]. Diabetologia, 2016, 59, 870-872.	2.9	2
129	Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome, 2016, 4, 17.	4.9	100
130	Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes, 2016, 65, 3765-3775.	0.3	62
131	Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia, 2016, 59, 2448-2458.	2.9	214
132	Autoimmune manifestations in aged mice arise from early-life immune dysregulation. Science Translational Medicine, 2016, 8, 361ra137.	5.8	38
133	Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nature Medicine, 2016, 22, 1482-1487.	15.2	232
134	Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease. Diabetes, 2016, 65, 3233-3239.	0.3	20
135	Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. Proteomics, 2016, 16, 1432-1446.	1.3	21
136	Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Human Pathology, 2016, 56, 93-100.	1.1	31
137	Presumptive Type 1 Diabetes With Comorbidities and Rapid Progression Despite Numerous Insulin-Positive Islets. Diabetes Care, 2016, 39, 1292-1294.	4.3	3
138	A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Diabetes, 2016, 65, 1310-1316.	0.3	34
139	The influence of type 1 diabetes on pancreatic weight. Diabetologia, 2016, 59, 217-221.	2.9	88
140	Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic βâ€cell function <i>via</i> glycogen synthase kinaseâ€3β. FASEB Journal, 2016, 30, 983-993.	0.2	16
141	Insulitis and \hat{I}^2 -Cell Mass in the Natural History of Type 1 Diabetes. Diabetes, 2016, 65, 719-731.	0.3	292
142	Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes. JCI Insight, 2016, 1, e88242.	2.3	108
143	A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Scientific Reports, $2015, 5, 13155$.	1.6	72
144	A run on the biobank. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 290-295.	1.2	36

#	Article	IF	Citations
145	The role for gut permeability in the pathogenesis of type 1 diabetes - a solid or leaky concept?. Pediatric Diabetes, 2015, 16, 485-492.	1.2	104
146	Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. PLoS ONE, 2015, 10, e0142318.	1.1	4
147	Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. Frontiers in Pharmacology, 2015, 6, 260.	1.6	55
148	Csf2 and Ptgs2 Epigenetic Dysregulation in Diabetes-prone Bicongenic B6.NODC11bxC1tb Mice. Genetics & Epigenetics, 2015, 7, GEG.S29696.	2.5	3
149	Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. Journal of Immunology, 2015, 195, 145-155.	0.4	219
150	Current Concepts on the Pathogenesis of Type 1 Diabetesâ€"Considerations for Attempts to Prevent and Reverse the Disease. Diabetes Care, 2015, 38, 979-988.	4.3	125
151	Beta-cell destruction and preservation in childhood and adult onset type 1 diabetes. Endocrine, 2015, 49, 693-702.	1.1	36
152	Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes. Diabetes, 2015, 64, 3873-3884.	0.3	22
153	The Streetlight Effect in Type 1 Diabetes. Diabetes, 2015, 64, 1081-1090.	0.3	66
154	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015, 38, 1964-1974.	4.3	690
155	Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes. Diabetes, 2015, 64, 3885-3890.	0.3	42
156	A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice. Clinical Immunology, 2015, 160, 90-102.	1.4	81
157	Early Childhood Gut Microbiomes Show Strong Geographic Differences Among Subjects at High Risk for Type 1 Diabetes. Diabetes Care, 2015, 38, 329-332.	4.3	79
158	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes, 2015, 64, 158-171.	0.3	80
159	Anti-thymocyte globulin/G-CSF treatment preserves \hat{l}^2 cell function in patients with established type 1 diabetes. Journal of Clinical Investigation, 2015, 125, 448-455.	3.9	140
160	Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Frontiers in Microbiology, 2014, 5, 678.	1.5	241
161	The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes () Tj ETQq1 1 (15, 1-9.	0.784314 rg 1.2	BT /Overlock 139
162	Nardilysin-Dependent Proteolysis of Cell-Associated VTCN1 (B7-H4) Marks Type 1 Diabetes Development. Diabetes, 2014, 63, 3470-3482.	0.3	25

#	Article	IF	Citations
163	Pancreatic biopsies in type 1 diabetes: revisiting the myth of Pandoraâ∈™s box. Diabetologia, 2014, 57, 656-659.	2.9	39
164	Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity. Diabetes, 2014, 63, 2006-2014.	0.3	154
165	Type 1 diabetes. Lancet, The, 2014, 383, 69-82.	6.3	1,863
166	Stem Cells to Insulin Secreting Cells: Two Steps Forward and Now a Time to Pause?. Cell Stem Cell, 2014, 15, 535-536.	5.2	39
167	Losing a Grip on the Notion of \hat{I}^2 -Cell Specificity for Immune Responses in Type 1 Diabetes: Can We Handle the Truth?. Diabetes, 2014, 63, 3572-3574.	0.3	22
168	Increased IFN-α–Producing Plasmacytoid Dendritic Cells (pDCs) in Human Th1-Mediated Type 1 Diabetes: pDCs Augment Th1 Responses through IFN-α Production. Journal of Immunology, 2014, 193, 1024-1034.	0.4	60
169	Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. Journal of Materials Chemistry B, 2014, 2, 2562-2574.	2.9	53
170	Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by <i>Lactococcus lactis</i> Reverses Diabetes in Recent-Onset NOD Mice. Diabetes, 2014, 63, 2876-2887.	0.3	129
171	The JDRF Network for the Pancreatic Organ Donor with Diabetes (nPOD): A novel Resource and Study Approach in Type 1 Diabetes Research. , 2013, , 245-255.		1
172	George S. Eisenbarth, 1947–2012. Diabetologia, 2013, 56, 435-438.	2.9	6
173	Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes, 2013, 62, 2595-2604.	0.3	381
174	Improving diabetes care in resource-poor countries: challenges and opportunities. Lancet Diabetes and Endocrinology,the, 2013, 1, 268-270.	5.5	19
175	Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 737-746.	2.0	106
176	The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFN \hat{I}^3 production by PBMC. Journal of Autoimmunity, 2013, 44, 8-12.	3.0	22
177	Trying to make a difference for those with Type 1 diabetes: a lesson in patience as well as a willingness to fail mightily. Expert Review of Endocrinology and Metabolism, 2013, 8, 323-327.	1.2	0
178	Global Reality of Type 1 Diabetes Care in 2013. Diabetes Care, 2013, 36, e144-e144.	4.3	3
179	Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes, 2013, 62, 9-17.	0.3	90
180	Increased Complement Activation in Human Type 1 Diabetes Pancreata. Diabetes Care, 2013, 36, 3815-3817.	4.3	44

#	Article	IF	CITATIONS
181	Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice. PLoS ONE, 2013, 8, e54712.	1.1	33
182	Novel detection of pancreatic and duodenal homeobox 1 autoantibodies (PAA) in human sera using luciferase immunoprecipitation systems (LIPS) assay. International Journal of Clinical and Experimental Pathology, 2013, 6, 1202-10.	0.5	2
183	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine, 2012, 209, 51-60.	4.2	572
184	Pancreas Organ Weight in Individuals With Disease-Associated Autoantibodies at Risk for Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 2337.	3.8	124
185	The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007641-a007641.	2.9	216
186	Collection Protocol for Human Pancreas. Journal of Visualized Experiments, 2012, , e4039.	0.2	25
187	Formation of a Human \hat{l}^2 -Cell Population within Pancreatic Islets Is Set Early in Life. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3197-3206.	1.8	273
188	Type 1 Diabetes. , 2012, , 65-94.		2
189	On the road to the insulin centenary. Lancet, The, 2012, 380, 1648.	6.3	11
190	Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2012, 28, 608-617.	1.7	178
191	Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia, 2012, 55, 2868-2877.	2.9	86
192	In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. American Journal of Stem Cells, 2012, 1, 114-127.	0.4	36
193	How Does Type 1 Diabetes Develop?. Diabetes, 2011, 60, 1370-1379.	0.3	199
194	Toward defining the autoimmune microbiome for type 1 diabetes. ISME Journal, 2011, 5, 82-91.	4.4	709
195	Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide. Diabetes Care, 2011, 34, 2567-2569.	4.3	61
196	The threshold hypothesis: solving the equation of nurture vs nature in type 1 diabetes. Diabetologia, 2011, 54, 2232-2236.	2.9	31
197	The pancreas in human type 1 diabetes. Seminars in Immunopathology, 2011, 33, 29-43.	2.8	56

#	Article	IF	CITATIONS
199	Progressive Erosion of \hat{l}^2 -Cell Function Precedes the Onset of Hyperglycemia in the NOD Mouse Model of Type 1 Diabetes. Diabetes, 2011, 60, 2086-2091.	0.3	64
200	Reduced Serum Vitamin D–Binding Protein Levels Are Associated With Type 1 Diabetes. Diabetes, 2011, 60, 2566-2570.	0.3	119
201	It's Time to Consider Changing the Rules. Diabetes, 2011, 60, 361-363.	0.3	8
202	Persistence is the Twin Sister of Excellence: TABLE 1. Diabetes, 2011, 60, 693-694.	0.3	18
203	Structure-Based Selection of Small Molecules To Alter Allele-Specific MHC Class II Antigen Presentation. Journal of Immunology, 2011, 187, 5921-5930.	0.4	66
204	Loss of Intra-Islet CD20 Expression May Complicate Efficacy of B-Cell–Directed Type 1 Diabetes Therapies. Diabetes, 2011, 60, 2914-2921.	0.3	65
205	Butyrate and Type 1 Diabetes Mellitus: Can We Fix the Intestinal Leak?. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 414-417.	0.9	37
206	Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. Journal of Diabetes and Its Complications, 2010, 24, 163-167.	1.2	20
207	Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method. PLoS ONE, 2010, 5, e11501.	1.1	156
208	Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats. PLoS ONE, 2010, 5, e10507.	1.1	227
209	Induction of Chimerism Permits Low-Dose Islet Grafts in the Liver or Pancreas to Reverse Refractory Autoimmune Diabetes. Diabetes, 2010, 59, 2228-2236.	0.3	19
210	The Juvenile Diabetes Research Foundation at Forty: Updates of Research in Type 1 Diabetes. Diabetes, 2010, 59, 1575-1577.	0.3	5
211	Efforts to Prevent and Halt Autoimmune Beta Cell Destruction. Endocrinology and Metabolism Clinics of North America, 2010, 39, 527-539.	1.2	10
212	Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer. PLoS ONE, 2010, 5, e11726.	1.1	139
213	Vitamin D Levels in Subjects With and Without Type 1 Diabetes Residing in a Solar Rich Environment. Diabetes Care, 2009, 32, 1977-1979.	4.3	69
214	Taking a Daily Vitamin to Prevent Type 1 Diabetes?. Diabetes, 2009, 58, 24-25.	0.3	12
215	Rabbit Polyclonal Mouse Antithymocyte Globulin Administration Alters Dendritic Cell Profile and Function in NOD Mice to Suppress Diabetogenic Responses. Journal of Immunology, 2009, 182, 4608-4615.	0.4	17
216	Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice. Diabetes, 2009, 58, 2277-2284.	0.3	68

#	Article	IF	CITATIONS
217	The road not taken: A path to curing type 1 diabetes?. European Journal of Immunology, 2009, 39, 2054-2058.	1.6	6
218	Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nature Immunology, 2009, 10, 1026-1033.	7.0	134
219	Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes. Diabetes, 2009, 58, 652-662.	0.3	333
220	Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes. Diabetes Care, 2009, 32, 2041-2046.	4.3	87
221	The pancreas in human type 1 diabetes: providing new answers to age-old questions. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 279-285.	1.2	59
222	Influence of Membrane CD25 Stability on T Lymphocyte Activity: Implications for Immunoregulation. PLoS ONE, 2009, 4, e7980.	1.1	59
223	Exendinâ€4 Therapy in NOD Mice with Newâ€Onset Diabetes Increases Regulatory T Cell Frequency. Annals of the New York Academy of Sciences, 2008, 1150, 152-156.	1.8	36
224	Autologous umbilical cord blood infusion for type 1 diabetes. Experimental Hematology, 2008, 36, 710-715.	0.2	136
225	Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation. Diabetes, 2008, 57, 405-414.	0.3	74
226	Neonatal Formula Feeding Leads to Immunological Alterations in an Animal Model of Type 1 Diabetes. Pediatric Research, 2008, 63, 303-307.	1.1	11
227	Combination Therapy With Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice. Diabetes, 2008, 57, 3281-3288.	0.3	169
228	The "Perfect Storm―for Type 1 Diabetes. Diabetes, 2008, 57, 2555-2562.	0.3	453
229	Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2337-2342.	3.3	54
230	Assessing theIn VitroSuppressive Capacity of Regulatory T Cells. Immunological Investigations, 2007, 36, 607-628.	1.0	51
231	Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genetics, 2007, 39, 1074-1082.	9.4	380
232	No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes. Diabetes, 2007, 56, 604-612.	0.3	214
233	Treg in type 1 diabetes. Cell Biochemistry and Biophysics, 2007, 48, 165-175.	0.9	47
234	Efficient delivery of siRNA into cytokine-stimulated insulinoma cells silences Fas expression and inhibits Fas-mediated apoptosis. FEBS Letters, 2006, 580, 553-560.	1.3	12

#	Article	IF	Citations
235	Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmunity Reviews, 2006, 5, 424-428.	2.5	62
236	$\hat{l}\pm 1$ -Antitrypsin Gene Therapy Modulates Cellular Immunity and Efficiently Prevents Type 1 Diabetes in Nonobese Diabetic Mice. Human Gene Therapy, 2006, 17, 625-634.	1.4	81
237	1-Antitrypsin Gene Therapy Modulates Cellular Immunity and Efficiently Prevents Type 1 Diabetes in Nonobese Diabetic Mice. Human Gene Therapy, 2006, .	1.4	0
238	Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes, 2006, 55, 171-8.	0.3	10
239	Changes in Intestinal Morphology and Permeability in the BioBreeding Rat Before the Onset of Type 1 Diabetes. Journal of Pediatric Gastroenterology and Nutrition, 2005, 40, 589-595.	0.9	135
240	Functional Defects and the Influence of Age on the Frequency of CD4+CD25+ T-Cells in Type 1 Diabetes. Diabetes, 2005, 54, 1407-1414.	0.3	344
241	Islet cell autoantibodies: a case of a premature obituary. Pediatric Diabetes, 2005, 6, 181-183.	1.2	6
242	Pancreatic regeneration in type 1 diabetes: dreams on a deserted islet?. Diabetologia, 2005, 48, 2200-2202.	2.9	17
243	Localized Gene Expression Following Administration of Adeno-associated Viral Vectors via Pancreatic Ducts. Molecular Therapy, 2005, 12, 519-527.	3.7	30
244	Diabetes Acceleration or Prevention by a Coxsackievirus B4 Infection: Critical Requirements for both Interleukin-4 and Gamma Interferon. Journal of Virology, 2005, 79, 1045-1052.	1.5	79
245	Neonatal Nutritional Interventions in the Prevention of Type 1 Diabetes. NeoReviews, 2005, 6, e220-e226.	0.4	1
246	A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation. Immunity, 2005, 23, 115-126.	6.6	297
247	Glucose transporter-2 (GLUT2) promoter mediated transgenic insulin production reduces hyperglycemia in diabetic mice. FEBS Letters, 2005, 579, 5759-5764.	1.3	24
248	Type 1 Diabetes Mellitus: Etiology, Presentation, and Management. Pediatric Clinics of North America, 2005, 52, 1553-1578.	0.9	140
249	Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nature Reviews Immunology, 2004, 4, 989-997.	10.6	187
250	Animal models have little to teach us about Type 1 diabetes: 1. In support of this proposal. Diabetologia, 2004, 47, 1650-1656.	2.9	86
251	In Vivo and In Vitro Characterization of Insulin-Producing Cells Obtained From Murine Bone Marrow. Diabetes, 2004, 53, 1721-1732.	0.3	366
252	Donor CD8+ T Cells Facilitate Induction of Chimerism and Tolerance without GVHD in Autoimmune NOD Mice Conditioned with Anti-CD3 mAb Blood, 2004, 104, 1204-1204.	0.6	4

#	Article	IF	CITATIONS
253	Timing of initial cereal exposure in infancy and risk of islet autoimmunity. Journal of Pediatrics, 2004, 144, 684-5.	0.9	O
254	Glucose-Responsive Expression of the Human Insulin Promoter in HepG2 Human Hepatoma Cells. Annals of the New York Academy of Sciences, 2003, 1005, 237-241.	1.8	19
255	Infant Diets and Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2003, 290, 1771.	3.8	17
256	Why Can't We Prevent Type 1 Diabetes?: Maybe it's time to try a different combination. Diabetes Care, 2003, 26, 3326-3328.	4.3	31
257	Systemic Overexpression of IL-10 Induces CD4+CD25+ Cell Populations In Vivo and Ameliorates Type 1 Diabetes in Nonobese Diabetic Mice in a Dose-Dependent Fashion. Journal of Immunology, 2003, 171, 2270-2278.	0.4	125
258	Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia, 2002, 45, 1350-1351.	2.9	12
259	Fatal attraction: chemokines and type 1 diabetes. Journal of Clinical Investigation, 2002, 110, 1611-1613.	3.9	16
260	Fatal attraction: chemokines and type 1 diabetes. Journal of Clinical Investigation, 2002, 110, 1611-1613.	3.9	12
261	Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet, The, 2001, 358, 221-229.	6.3	1,244
262	Ingested IFN- \hat{l} ±Preserves Residual \hat{l}^2 Cell Function in Type 1 Diabetes. Journal of Interferon and Cytokine Research, 2001, 21, 1021-1030.	0.5	23
263	The NOD mouse model of type 1 diabetes: As good as it gets?. Nature Medicine, 1999, 5, 601-604.	15.2	548
264	Autoreactive T cell Responses in Insulin-dependent (Type 1) Diabetes Mellitus. Report of the First International Workshop for Standardization of T cell assays. Journal of Autoimmunity, 1999, 13, 267-282.	3.0	121
265	Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature, 1998, 391, 177-181.	13.7	639
266	Aging and the Immune Response to Tetanus Toxoid: Diminished Frequency and Level of Cellular Immune Reactivity to Antigenic Stimulation. Vaccine Journal, 1998, 5, 894-896.	2.6	36
267	Retardation or Acceleration of Diabetes in NOD/Lt Mice Mediated by Intrathymic Administration of Candidate \hat{I}^2 -Cell Antigens. Diabetes, 1997, 46, 1975-1982.	0.3	65
268	Molecular Mimicry and the Pathogenesis of Insulin-dependent Diabetes Mellitus: Still Just an Attractive Hypothesis. Annals of Medicine, 1997, 29, 393-399.	1.5	10
269	Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes–prone mice. Nature Medicine, 1996, 2, 1348-1353.	15.2	249
270	Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Trends in Immunology, 1994, 15, 115-120.	7.5	114

#	ARTICLE	IF	CITATIONS
271	The Pathogenesis of Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1994, 331, 1428-1436.	13.9	921
272	Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature, 1993, 366, 69-72.	13.7	1,125
273	Lack of Immune Responsiveness to Bovine Serum Albumin in Insulin-Dependent Diabetes. New England Journal of Medicine, 1993, 329, 1853-1858.	13.9	154
274	Is Insulin-Dependent Diabetes Mellitus Environmentally Induced?. New England Journal of Medicine, 1992, 327, 348-349.	13.9	39
275	Inherited Susceptibility to Insulin-Dependent Diabetes is Associated with HLA-DR1, while DR5 is Protective. Autoimmunity, 1988, 1, 197-205.	1.2	32
276	Dietary Protein Restriction Reduces the Frequency and Delays the Onset of Insulin Dependent Diabetes in BB Rats. Autoimmunity, 1988, 2, 11-19.	1.2	25
277	The Possible Role of Enteroviruses in Diabetes Mellitus. , 0, , 353-385.		26